CVR: 39308967
Previous names: Integrated biomedical technologies ApS, IBIO TECH ApS
Aptol Pharma ApS was a Danish company of the type Anpartsselskab based in København SV, founded in 2018. The company was registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named IBIO TECH ApS and Integrated biomedical technologies ApS. The company's owners include Tue Wenzel Kragstrup, Peter Andreas Nicolai Reumert Wagtmann and ADT HOLDING ApS. In 2024, the company reported a gross profit of DKK 2,442 and a net result of DKK -131,289 compared with DKK 307,979 the year before. Equity amounted to DKK -140,336.
Selskabets formål er at udvikle nye lægemidler alene eller i partnerskaber.
Ved dekret af 28. april 2026 har Sø- og Handelsrettens skifteret taget Aptol Pharma ApS under konkursbehandling. Kurator: Advokat Jacob Smith, August Bournonvilles Passage 1, 1055 København K. Sagsnr. K 847/26-K.
Source: Statstidende — updated daily
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationCompared to 1.052 companies in Forskning og eksperimentel udvikling inden for naturvidenskab og teknik
Comparison is based on industry median values
Screen owners and management against the Danish FSA's official PEP lists
Contact info changed: new phone: 26784520, new email: [email protected], new website: aptolpharma.com (May 2, 2026).
On May 2, 2026, Aptol Pharma ApS was placed under bankruptcy proceedings.
On April 30, 2026, a notice regarding Aptol Pharma ApS was published in Statstidende: Konkursdekret (S28042026-218).
As of April 28, 2026, Kira Gerber Astakhova has left the board of directors of Aptol Pharma ApS.
As of April 28, 2026, Peter Andreas Nicolai Reumert Wagtmann has left the board of directors of Aptol Pharma ApS.
As of April 28, 2026, Kira Gerber Astakhova has stepped down as director of Aptol Pharma ApS.
As of November 28, 2025, Mads Hartvig Clausen has left the board of directors of Aptol Pharma ApS.
As of November 28, 2025, Peter Andreas Nicolai Reumert Wagtmann is registered as an owner of Aptol Pharma ApS with an ownership share of 10%.
As of November 28, 2025, ADT HOLDING ApS is registered as an owner of Aptol Pharma ApS with an ownership share of 10%.
As of September 1, 2025, KGAA Holding ApS is registered as an owner of Aptol Pharma ApS with an ownership share of 33%.
As of July 31, 2025, Mads Hartvig Clausen has joined the board of directors of Aptol Pharma ApS.
As of July 31, 2025, Anders Dyhr Dombernowsky-Toft has left the board of directors of Aptol Pharma ApS.
As of July 30, 2025, Mads Hartvig Clausen has left the board of directors of Aptol Pharma ApS.
As of February 28, 2025, Tue Wenzel Kragstrup is registered as an owner of Aptol Pharma ApS with an ownership share of 15%.
As of February 28, 2025, is registered as an owner of Aptol Pharma ApS with an ownership share of 15%.
Aptol Pharma ApS has published its annual report for 2024. Gross profit came to DKK 2,442, and the net result was DKK -131,289.
As of February 16, 2024, Mads Hartvig Clausen has joined the board of directors of Aptol Pharma ApS.
Aptol Pharma ApS has published its annual report for 2023. Gross profit came to DKK 414,462, and the net result was DKK 307,979.
As of October 27, 2023, Peter Andreas Nicolai Reumert Wagtmann has joined the board of directors of Aptol Pharma ApS.
As of August 21, 2023, Anders Dyhr Dombernowsky-Toft has joined the board of directors of Aptol Pharma ApS.
Aptol Pharma ApS has published its annual report for 2022. Gross profit came to DKK -421,544, and the net result was DKK -334,362.
On May 25, 2022, the company changed its name from IBIO TECH ApS to Aptol Pharma ApS.
Aptol Pharma ApS has published its annual report for 2021. Revenue came to DKK 0, and the net result was DKK 0.
Aptol Pharma ApS has published its annual report for 2020. Revenue came to DKK 0, and the net result was DKK -2,464.
Aptol Pharma ApS has published its annual report for 2019. Revenue came to DKK 0, and the net result was DKK -2,348.
As of December 13, 2019, Kira Gerber Astakhova has joined the board of directors of Aptol Pharma ApS.
On December 13, 2019, the company changed its name from Integrated biomedical technologies ApS to IBIO TECH ApS.
As of December 12, 2019, Kira Gerber Astakhova has left the board of directors of Aptol Pharma ApS.
Aptol Pharma ApS has published its interim report for the period February 5, 2018 – December 31, 2018.
As of February 5, 2018, Kira Gerber Astakhova has joined the board of directors of Aptol Pharma ApS.
As of February 5, 2018, Kira Gerber Astakhova is registered as director of Aptol Pharma ApS.
Aptol Pharma ApS was founded on February 5, 2018.
Companies in the same industry and area
CVR 19352102
CVR 44931885
CVR 44214032
CVR 46354834
CVR 37065226
companydata.dk